Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia

Tervonen, HE; Chen, TYT; Lin, E; Boyle, FM; Moylan, EJ; Della-Fiorentina, SA; Beith, J; Johnston, A; Currow, DC

Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia

Tervonen, HE Chen, TYT Lin, E Boyle, FM Moylan, EJ Della-Fiorentina, SA Beith, J Johnston, A Currow, DC

Permalink

Publication Type:: Journal Article
Citation:: European Journal of Cancer Care, 2019, 28 (5)
Issue Date:: 2019-09-01

Closed Access

	Filename	Description	Size
	Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia.pdf	Published Version	474.33 kB		View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Tervonen, HE	en_US
dc.contributor.author	Chen, TYT	en_US
dc.contributor.author	Lin, E	en_US
dc.contributor.author	Boyle, FM	en_US
dc.contributor.author	Moylan, EJ	en_US
dc.contributor.author	Della-Fiorentina, SA	en_US
dc.contributor.author	Beith, J	en_US
dc.contributor.author	Johnston, A	en_US
dc.contributor.author	Currow, DC https://orcid.org/0000-0003-1988-1250	en_US
dc.date.available	2019-05-27	en_US
dc.date.issued	2019-09-01	en_US
dc.identifier.citation	European Journal of Cancer Care, 2019, 28 (5)	en_US
dc.identifier.issn	0961-5423	en_US
dc.identifier.uri	http://hdl.handle.net/10453/139196
dc.description.abstract	© 2019 John Wiley & Sons Ltd Objective: To examine risk of emergency hospital admission and survival following adjuvant chemotherapy for early breast cancer. Methods: Linked data from New South Wales population-based and clinical cancer registries (2008–2012), hospital admissions, official death records and pharmaceutical benefit claims. Women aged ≥18 years receiving adjuvant chemotherapy for early-stage operable breast cancer in NSW public hospitals were included. Odds ratios (OR) for emergency hospitalisation within 6 months following chemotherapy initiation were estimated using logistic regression and survival using Kaplan–Meier and Cox proportional hazards methods. Results: A total of 3,950 women were included and 30.6% were hospitalised. The most common principal diagnosis at admission was neutropenia (30.8%). Women receiving docetaxel/carboplatin/trastuzumab (TCH) and docetaxel/cyclophosphamide (TC) were the most frequently hospitalised. After adjustment for demographic and clinical factors, the increased risk of hospitalisation for TCH and TC remained compared with doxorubicin/cyclophosphamide 3-weekly (OR 1.71, 95% confidence interval [CI] 1.24–2.37 and OR 1.47, 95% CI 1.17–1.85 respectively). Five-year overall survival was similar for women who were (92.2%, 95% CI 90.7–93.8) and were not hospitalised (93.1%, 95% CI 92.1–94.1). Conclusion: Emergency hospitalisations following chemotherapy for early breast cancer were relatively common, especially following docetaxel-containing protocols. Further examination of reasons for admission is needed to inform actions to improve patient safety.	en_US
dc.relation.ispartof	European Journal of Cancer Care	en_US
dc.relation.isbasedon	10.1111/ecc.13125	en_US
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.classification	Oncology & Carcinogenesis	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Breast Neoplasms	en_US
dc.subject.mesh	Neutropenia	en_US
dc.subject.mesh	Emergencies	en_US
dc.subject.mesh	Fever	en_US
dc.subject.mesh	Cyclophosphamide	en_US
dc.subject.mesh	Carboplatin	en_US
dc.subject.mesh	Antineoplastic Combined Chemotherapy Protocols	en_US
dc.subject.mesh	Chemotherapy, Adjuvant	en_US
dc.subject.mesh	Hospitalization	en_US
dc.subject.mesh	Mastectomy	en_US
dc.subject.mesh	Mastectomy, Segmental	en_US
dc.subject.mesh	Survival Rate	en_US
dc.subject.mesh	Logistic Models	en_US
dc.subject.mesh	Proportional Hazards Models	en_US
dc.subject.mesh	Odds Ratio	en_US
dc.subject.mesh	Risk Factors	en_US
dc.subject.mesh	Retrospective Studies	en_US
dc.subject.mesh	Cohort Studies	en_US
dc.subject.mesh	Adult	en_US
dc.subject.mesh	Aged	en_US
dc.subject.mesh	Middle Aged	en_US
dc.subject.mesh	New South Wales	en_US
dc.subject.mesh	Female	en_US
dc.subject.mesh	Kaplan-Meier Estimate	en_US
dc.subject.mesh	Chemotherapy-Induced Febrile Neutropenia	en_US
dc.subject.mesh	Trastuzumab	en_US
dc.subject.mesh	Docetaxel	en_US
dc.subject.mesh	Infections	en_US
dc.title	Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia	en_US
dc.type	Journal Article
utslib.citation.volume	5	en_US
utslib.citation.volume	28	en_US
utslib.for	1110 Nursing	en_US
utslib.for	1112 Oncology and Carcinogenesis	en_US
utslib.for	1117 Public Health and Health Services	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/IMPACCT
utslib.copyright.status	closed_access	*
pubs.issue	5	en_US
pubs.publication-status	Published	en_US
pubs.volume	28	en_US

Abstract:

© 2019 John Wiley & Sons Ltd Objective: To examine risk of emergency hospital admission and survival following adjuvant chemotherapy for early breast cancer. Methods: Linked data from New South Wales population-based and clinical cancer registries (2008–2012), hospital admissions, official death records and pharmaceutical benefit claims. Women aged ≥18 years receiving adjuvant chemotherapy for early-stage operable breast cancer in NSW public hospitals were included. Odds ratios (OR) for emergency hospitalisation within 6 months following chemotherapy initiation were estimated using logistic regression and survival using Kaplan–Meier and Cox proportional hazards methods. Results: A total of 3,950 women were included and 30.6% were hospitalised. The most common principal diagnosis at admission was neutropenia (30.8%). Women receiving docetaxel/carboplatin/trastuzumab (TCH) and docetaxel/cyclophosphamide (TC) were the most frequently hospitalised. After adjustment for demographic and clinical factors, the increased risk of hospitalisation for TCH and TC remained compared with doxorubicin/cyclophosphamide 3-weekly (OR 1.71, 95% confidence interval [CI] 1.24–2.37 and OR 1.47, 95% CI 1.17–1.85 respectively). Five-year overall survival was similar for women who were (92.2%, 95% CI 90.7–93.8) and were not hospitalised (93.1%, 95% CI 92.1–94.1). Conclusion: Emergency hospitalisations following chemotherapy for early breast cancer were relatively common, especially following docetaxel-containing protocols. Further examination of reasons for admission is needed to inform actions to improve patient safety.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/139196